ADMA Biologics Confirms Large Accelerated Filer Status in Q2 2025 10-Q
Ticker: ADMA · Form: 10-Q · Filed: Aug 6, 2025 · CIK: 1368514
| Field | Detail |
|---|---|
| Company | Adma Biologics, Inc. (ADMA) |
| Form Type | 10-Q |
| Filed Date | Aug 6, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, SEC Filing, Biologics, Regulatory Compliance, Nasdaq, Large Accelerated Filer, Quarterly Report
Related Tickers: ADMA
TL;DR
ADMA Biologics' clean 10-Q filing confirms strong regulatory compliance, signaling a stable, transparent operation for investors.
AI Summary
ADMA Biologics, Inc. filed its 10-Q for the quarter ended June 30, 2025, indicating it is a large accelerated filer and has met all SEC filing requirements. The company, incorporated in Delaware with IRS Employer Identification No. 56-2590442, operates in the biological products sector. Its common stock is traded on the Nasdaq Global Market under the symbol ADMA. The filing confirms the company's compliance with electronic data submission requirements under Rule 405 of Regulation S-T. No specific revenue or net income figures were provided in the excerpt, nor were details on key business changes, risks, or strategic outlook. The report primarily focuses on the company's filing status and general corporate information.
Why It Matters
For investors, ADMA Biologics' status as a large accelerated filer signals a higher level of scrutiny and reporting requirements, potentially indicating greater transparency and market confidence compared to smaller companies. This compliance with SEC regulations, including electronic data submission, ensures timely access to financial information, which is crucial for informed investment decisions. In a competitive biotech landscape, adherence to such standards can enhance a company's reputation and attract institutional investors. Employees and customers benefit from the stability and regulatory adherence implied by this filing status, suggesting a well-managed and accountable organization.
Risk Assessment
Risk Level: low — The risk level is low based on the provided excerpt because it primarily details ADMA Biologics' compliance with SEC filing requirements, including being a large accelerated filer and submitting all required Interactive Data Files. There is no mention of financial distress, operational challenges, or significant legal issues, suggesting a stable regulatory standing.
Analyst Insight
Investors should view ADMA Biologics' consistent regulatory compliance as a positive indicator of corporate governance and transparency. While this filing doesn't provide financial performance, it suggests a well-managed company, which is a foundational element for long-term investment consideration.
Key Numbers
- 001-36728 — Commission File Number (Identifies ADMA Biologics' registration with the SEC)
- 56-2590442 — IRS Employer Identification Number (Unique tax identification for ADMA Biologics)
- 20250630 — Conformed Period of Report (Indicates the quarter ended June 30, 2025, for this 10-Q filing)
- 20250806 — Filed As Of Date (The date the 10-Q was officially filed with the SEC)
Key Players & Entities
- ADMA BIOLOGICS, INC. (company) — Registrant as specified in its charter
- Delaware (regulator) — State of incorporation
- 56-2590442 (dollar_amount) — I.R.S. Employer Identification No.
- Nasdaq Global Market (regulator) — Exchange on which Common Stock is registered
- 001-36728 (dollar_amount) — Commission file number
- SEC (regulator) — Securities and Exchange Commission
- Rule 405 of Regulation S-T (regulator) — Regulation for Interactive Data File submission
- June 30, 2025 (dollar_amount) — End of the quarterly period reported
- August 6, 2025 (dollar_amount) — Date of filing
- 465 State Route 17, Ramsey, New Jersey 07446 (company) — Address of principal executive offices
FAQ
What is ADMA Biologics' filing status for the quarter ended June 30, 2025?
ADMA Biologics is a large accelerated filer for the quarter ended June 30, 2025, as indicated in its 10-Q filing.
Has ADMA Biologics filed all required reports with the SEC?
Yes, ADMA Biologics has filed all reports required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months.
Is ADMA Biologics compliant with electronic data submission requirements?
Yes, ADMA Biologics has submitted every Interactive Data File required pursuant to Rule 405 of Regulation S-T during the preceding 12 months.
Where is ADMA Biologics' common stock traded?
ADMA Biologics' common stock is traded on the Nasdaq Global Market under the trading symbol ADMA.
What is the fiscal year end for ADMA Biologics?
ADMA Biologics' fiscal year end is December 31, as stated in the filing.
What is ADMA Biologics' state of incorporation?
ADMA Biologics is incorporated in Delaware.
What is the business phone number for ADMA Biologics?
The business phone number for ADMA Biologics is (201) 478-5552.
What is the primary business classification of ADMA Biologics?
ADMA Biologics' Standard Industrial Classification is Biological Products (No Diagnostic Substances) [2836].
When was ADMA Biologics' 10-Q for Q2 2025 filed?
The 10-Q for the quarterly period ended June 30, 2025, was filed on August 6, 2025.
Is ADMA Biologics considered an emerging growth company?
No, ADMA Biologics has indicated that it is not an emerging growth company.
Industry Context
ADMA Biologics operates within the biological products sector, which is characterized by significant research and development investment, stringent regulatory oversight, and a focus on specialized therapeutic areas. The industry is competitive, with companies vying for market share in areas like plasma-derived biologics and vaccines. Trends include advancements in biotechnology, increasing demand for specialized treatments, and evolving regulatory pathways for drug approval.
Regulatory Implications
As a biological products company, ADMA Biologics is subject to extensive regulation by bodies such as the Food and Drug Administration (FDA). Compliance with manufacturing standards, clinical trial protocols, and post-market surveillance is critical. Any deviations can lead to significant delays, fines, or product recalls, impacting financial performance and market access.
What Investors Should Do
- Monitor upcoming earnings reports for detailed financial performance.
- Review the company's product pipeline and clinical trial updates.
- Assess competitive landscape and market penetration strategies.
Key Dates
- 2025-06-30: Quarterly period end — Marks the end of the reporting period for the 10-Q filing.
- 2025-08-06: 10-Q Filing Date — Indicates the official submission date of the quarterly report to the SEC.
Glossary
- 10-Q
- A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document is the primary source of financial information for the period ended June 30, 2025.)
- Large accelerated filer
- A filer that meets certain criteria, including having a public float of $700 million or more, and has been subject to SEC reporting requirements for at least 12 calendar months. (ADMA Biologics qualifies as a large accelerated filer, indicating a certain size and maturity.)
- Regulation S-T
- A regulation of the SEC governing the preparation and submission of filings in electronic format. (ADMA Biologics has confirmed compliance with electronic filing requirements under Rule 405 of this regulation.)
- Nasdaq Global Market
- A stock exchange operated by Nasdaq, Inc., which lists many of the largest and most liquid companies. (ADMA Biologics' common stock is traded on this major exchange, indicating its public market presence.)
Year-Over-Year Comparison
This filing is for the quarter ended June 30, 2025. As specific financial metrics like revenue, net income, and margins were not detailed in the provided excerpt, a direct comparison to the previous year's filing (e.g., June 30, 2024) is not possible. Similarly, changes in risk factors or strategic outlook cannot be assessed without more detailed content from both filings.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on August 6, 2025 regarding ADMA BIOLOGICS, INC. (ADMA).